Assyrians
Assyrians are also strong believers in the evil eye. They will usually wear a blue/turquoise bead around a necklace to be protected from the evil eye. Also, they might pinch the buttocks, comparable to Armenians. It is said that people with green or blue eyes are more prone to the evil eye effect. Turkey
A typical nazar is made of handmade glass featuring concentric circles or teardrop shapes in dark blue, white, light blue and black, occasionally with a yellow/gold edge.Cultures that have nazars or some variation include Turkey, Romania, Albania, North Macedonia, Bosnia and Herzegovina, Greece, Cyprus, Syria, Lebanon, Jordan, Palestine, Egypt, Armenia, Iran, India, Israel, Pakistan, Uzbekistan, Afghanistan, Türkmenistan, Iraq and Azerbaijan, where the nazar is often hung in homes, offices, cars, childrens clothing, or incorporated in jewellery and ornaments.They are a popular choice of souvenir with tourists. Ethiopia
Belief in the evil eye, or buda (var. bouda), is widespread in Ethiopia. Buda is generally believed to be a power held and wielded by those in a different social group, for example among the metalworkers. Some Ethiopian Christians carry an amulet or talisman, known as a kitab, or will invoke Gods name, to ward off the ill effects of buda. A debtera, who is either an unordained priest or educated layperson, will create these protective amulets or talismans. Senegal
The equivalent of the evil eye in Wolof would be the "thiat". It is believed that beautiful objects may break if enviously stared at by others.
In 1953, gamma globulin was shown to prevent paralytic polio.Being a product derived from bone marrow and lymph gland cells, gamma globulin injections, along with blood transfusions and intravenous drug use, can pass hepatitis C to their recipients. Once hepatitis C was identified in 1989, blood banks began screening all blood donors for the presence of the virus in their bloodstream. However, since hepatitis C is known to have been present since at least the 1940s, a gamma globulin shot received prior to the early 1990s put the recipient at risk of being infected. Intravenous gamma globulin was FDA-approved in 2004 to reduce antibodies in a patient with kidney failure to allow that person to accept a kidney from a donor with a different blood type (ABO-incompatible), or who is an unacceptable tissue match. Stanley Jordan at Cedars-Sinai Medical Center in Los Angeles pioneered this treatment. Pathology
An excess is known as hypergammaglobulinemia. A deficiency is known as hypogammaglobulinemia. A disease of gamma globulins is called a "gammopathy" (for example, in monoclonal gammopathy of undetermined significance). References
External links
gamma-Globulins at the US National Library of Medicine Medical Subject Headings (MeSH)